210 related articles for article (PubMed ID: 37313955)
1. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
Bansal S; Zamarripa CA; Spindle TR; Weerts EM; Thummel KE; Vandrey R; Paine MF; Unadkat JD
Clin Pharmacol Ther; 2023 Sep; 114(3):693-703. PubMed ID: 37313955
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes.
Bansal S; Paine MF; Unadkat JD
Drug Metab Dispos; 2022 Apr; 50(4):351-360. PubMed ID: 35115300
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions.
Nasrin S; Watson CJW; Perez-Paramo YX; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1070-1080. PubMed ID: 34493602
[TBL] [Abstract][Full Text] [Related]
5. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
[TBL] [Abstract][Full Text] [Related]
7. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.
Ryu JY; Song IS; Sunwoo YE; Shon JH; Liu KH; Cha IJ; Shin JG
Clin Pharmacol Ther; 2007 Nov; 82(5):531-40. PubMed ID: 17392720
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
[TBL] [Abstract][Full Text] [Related]
9. Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450.
Bansal S; Maharao N; Paine MF; Unadkat JD
Drug Metab Dispos; 2020 Oct; 48(10):1008-1017. PubMed ID: 32587099
[TBL] [Abstract][Full Text] [Related]
10. Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.
Kim MG; Kim Y; Jeon JY; Kim DS
Br J Clin Pharmacol; 2016 Dec; 82(6):1580-1590. PubMed ID: 27495955
[TBL] [Abstract][Full Text] [Related]
11. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.
Qian Y; Gurley BJ; Markowitz JS
J Clin Psychopharmacol; 2019; 39(5):462-471. PubMed ID: 31433338
[TBL] [Abstract][Full Text] [Related]
12. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
Jenkins J; Williams D; Deng Y; Collins DA; Kitchen VS
Eur J Clin Pharmacol; 2010 Jan; 66(1):67-76. PubMed ID: 19756558
[TBL] [Abstract][Full Text] [Related]
13. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
Armani S; Ting L; Sauter N; Darstein C; Tripathi AP; Wang L; Zhu B; Gu H; Chun DY; Einolf HJ; Kulkarni S
Clin Drug Investig; 2017 May; 37(5):465-472. PubMed ID: 28155129
[TBL] [Abstract][Full Text] [Related]
14. A Comprehensive In Vivo and In Vitro Assessment of the Drug Interaction Potential of Red Ginseng.
Seong SJ; Kang WY; Heo JK; Jo J; Choi WG; Liu KH; Lee S; Choi MK; Han YH; Lee HS; Ohk B; Lee HW; Song IS; Yoon YR
Clin Ther; 2018 Aug; 40(8):1322-1337. PubMed ID: 30078466
[TBL] [Abstract][Full Text] [Related]
15. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
[TBL] [Abstract][Full Text] [Related]
16. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
Sholler DJ; Spindle TR; Cone EJ; Goffi E; Kuntz D; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
J Anal Toxicol; 2022 May; 46(5):494-503. PubMed ID: 34089060
[TBL] [Abstract][Full Text] [Related]
17. Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Stemkens R; Jager Vd; Dawson R; Diacon AH; Narunsky K; Padayachee SD; Boeree MJ; van Beek SW; Colbers A; Coenen MJH; Svensson EM; Fuhr U; Phillips PPJ; Te Brake LHM; Aarnoutse RE;
Antimicrob Agents Chemother; 2023 Oct; 67(10):e0068323. PubMed ID: 37768317
[TBL] [Abstract][Full Text] [Related]
18. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
[TBL] [Abstract][Full Text] [Related]
20. Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently.
Duthaler U; Bachmann F; Suenderhauf C; Grandinetti T; Pfefferkorn F; Haschke M; Hruz P; Bouitbir J; Krähenbühl S
Clin Pharmacokinet; 2022 Jul; 61(7):1039-1055. PubMed ID: 35570253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
